This study assessed the diagnostic value of [ 18 F]FDG-PET/CT in staging histological subtypes (HSs) of invasive bladder cancer. In 112 patients with ≥ 75% HS-content, 87% of primary tumours were FDG-avid, 9% were non-assessable (due to high FDG-avid urine), and only 5% were FDG-negative. [ 18 F]FDG-PET/CT altered staging in 20% of patients, predominantly through upstaging, with little variation across HSs or between pure and mixed content. A matched cohort with conventional urothelial carcinoma showed comparable staging-modification rates. Although pathological confirmation was limited to a selected subgroup, these results support [ 18 F]FDG-PET/CT as a complementary staging modality in both conventional and rare bladder cancer subtypes, with potential to improve staging accuracy and treatment planning.
No takes yet. Share an insight, caveat, or question.
Lijnen et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: